Clinical-stage biopharmaceutical company Entrada Therapeutics Inc. (TRDA) has been steadily progressing its pipeline of therapies for neuromuscular diseases, with several key milestones expected in 2026. The company's focus on Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) positions it at the forefront of innovation in rare disease treatment.
Key Catalysts Ahead
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.